In this study, we use competitive repopulation to compare the quality and frequency of stem cells isolated from mobilized blood with stem cells isolated from bone marrow (BM) in a mouse model. Lin À Sca-1 þ c-Kit þ (LSK) cells were harvested from control BM and peripheral blood of mice following granulocyte colony-stimulating factor (G-CSF) administration. LSK cells were used because of their resemblance to human CD34 þ cells. We confirmed that transplantation of phenotypically defined mobilized peripheral blood (MPB) stem cells results in rapid recovery of blood counts. However, in vitro results indicated that LSK cells purified from MPB had lower cobblestone areaforming cell day 35 activity compared to BM. Additionally, evaluation of chimerism after co-transplantation of LSK cells purified from blood and BM revealed that MPB stem cells contained 25-fold less repopulation potential compared to BM stem cells. Competitive repopulating unit frequency analysis showed that freshly isolated MPB LSK cells have 8.8-fold fewer cells with long-term repopulating ability compared to BM LSK cells. Secondary transplantation showed no further decline in contribution of hematopoiesis relative to BM. We conclude that the reduced frequency of stem cells within the LSK population of MPB, rather than poorer quality, causes the reduced repopulation potential.
Introduction
The initial source of hematopoietic cells used for transplantation was bone marrow (BM). 1 However, owing to the faster regeneration of both circulating neutrophils (9-11 days) 2,3 and platelets, peripheral blood stem cells have become the primary source of hematopoietic stem cells for clinical transplantation over the past 10 years. 4 Although multiple hematopoietic growth factors are capable of inducing mobilization of hematopoietic progenitors, granulocyte colony-stimulating factor (G-CSF) is at present the most used mobilizing molecule in clinical protocols. 5 The ability of G-CSF to mobilize BM precursors and long-term repopulating cells was initially shown in preclinical studies. Molineux et al. 6 observed a marked increase in the colony-forming unit spleen pool in the peripheral blood of mice treated with repeated doses of G-CSF. In addition, it was observed that G-CSF alone and in combination with stem cell factor or interleukin-7 mobilizes hematopoietic precursors capable of both radioprotection and generating sustained lymphohematopoiesis in transplanted recipients. 7 In vitro data from human patients appear consistent with the concept that the quality of human mobilized peripheral blood (MPB) progenitor cells is at least equivalent to that corresponding to BM grafts. 8, 9 Surprisingly, despite the prevalent use of hematopoietic stem cell mobilization in clinical transplantation, few reports exist describing the competitive repopulating quality of mobilized stem cells compared to BM stem cells following G-CSF treatment. Most available reports only outlined the differences in the kinetics and efficiency of engraftment, in homing properties and in cell cycle profiles between mobilized blood stem cells and those isolated from resting BM. [10] [11] [12] [13] In view of the increased use of peripheral blood stem cells in clinical transplant settings, it is of relevance to investigate long-term functioning of stem cells isolated from different sources. In this study, we directly assessed the function of MPB stem cells compared to control BM stem cells when co-transplanted in a single recipient mouse in an in vivo competitive repopulation assay. We show a reduced frequency of repopulating stem cells in purified G-CSF-MPB Lin 
Materials and methods

Mice
Female C57BL/6 (B6), C57BL/6.SJL (CD45.1), (C57BL/ 6 Â C57BL6.SJL) F 1 (CD45.1/2) or C57BL/6-Tg(ACTB-EGFP)10sb/J transgenic GFP (GFP) mice were used as donors, competitors or recipients of blood and marrow stem cells depending on the experimental model. CD45.1 and transgenic GFP mice were originally obtained from the Jackson Laboratory (Bar Harbor, ME, USA) and bred in our local animal facility. Wild-type female B6 mice were purchased from Harlan (Horst, The Netherlands) and maintained under clean conventional conditions in the animal facilities of University Medical Centre Groningen (The Netherlands). Mice were fed ad libitum with food pellets and acidified tap water (pH ¼ 2.8). All animal procedures were approved by the local animal ethics committee of the University Medical Centre Groningen.
Mobilization and harvesting of stem cells BM cells were harvested by flushing the femoral shaft with a-Modified Eagle's Medium (GibcoBRL, Invitrogen, CA, USA) supplemented with 2% fetal calf serum (FCS; GibcoBRL, Invitrogen, CA, USA). Pegylated G-CSF (Neulasta) (Amgen, Thousand Oaks, CA, USA) (250 mg/ kg/mouse) was used to mobilize stem cells.
14 Two doses of G-CSF were subcutaneously administered to donor mice at day À6 and day À3 before stem cell harvest. MPB cells were harvested by cardiac puncture. Approximately 1 ml of blood was collected and was diluted with 4 ml of Iscove's modified Dulbecco's modified Eagle's medium (IMDM; GibcoBRL, Paisley, Scotland) supplemented with 5% FCS (GibcoBRL, Invitrogen, CA, USA) and heparin (25 IU) (Leo Pharma, Breda, Netherlands). The collected blood cell suspension (5 ml) was centrifuged over an equal volume of Lympholyte-M (Cedarlane Laboratories Ltd, Hornby, Canada) at 400 Â g for 30 min at room temperature. After centrifugation, the mononuclear cells within the opaque interface layer were isolated and washed in IMDM/5% FCS for 5 min at 2000 r.p.m. at 41C. Alternatively, red blood cells were lysed using ammonium chloride (NH 4 Cl) without prior density separation. Nucleated cells were measured on a Coulter Counter Model Z2 (Coulter Electronics, Hialeah, FL, USA).
Isolation of LSK cells
BM and MPB cells were stained as described previously 15 with biotinylated lineage-specific Mouse Lineage Panel antibodies, containing anti-CD45R, anti-CD11b, anti-TER119, anti-Gr-1 and anti-CD3e (BD Pharmingen, San Diego, CA, USA), fluorescein isothiocyanate (FITC)-antiSca-1 and APC-anti-c-kit (BD Pharmingen, San Diego, CA, USA). Biotinylated antibodies were visualized with streptavidin-phycoerythrin (PE) (Pharmingen, San Diego, CA, USA). After antibody staining, cells were sorted by a MoFlow cell sorter (DakoCytomation, Fort Collins, CO, USA). LSK and Lin À non-Sca-1 þ c-Kit þ cells were sorted and used in transplantation assays or in in vitro cobblestone area-forming cell (CAFC) assays.
Long-term competitive repopulation ability Female B6, CD45.1 or transgenic GFP mice were used as donors for competitor cells. Female B6 mice were used as recipients in all experiments. Recipient mice were irradiated with 9.5 Gy g-rays (0.7026 Gy/min) in a CIS Biointer- ). Twelve weeks after transplantation, donor cell contribution in the peripheral blood was determined. Recipients with a contribution of X5% in both myeloid and lymphoid lineages were considered to be positive.
To evaluate and quantify the repopulating potential of mobilized blood LSK cells and control BM LSK cells, the frequency of competitive repopulation units (CRU) was calculated. CRU frequencies per 1000 LSK were calculated from the resultant percentage positive recipients by limiting dilution analysis procedures which uses Poisson statistics. 16 CAFC assays CAFC assays were performed as described [17] [18] [19] to assess the number of hematopoietic progenitor cells (CAFC day 7) or more primitive stem cells (CAFC day 35) in MPB stem cells.
Secondary transplantations
In one of the competitive repopulation experiments, in which recipients were transplanted in different ratios with CD45.1 MPB LSK cells and CD45.2 BM LSK competitor cells, mice were killed for secondary transplantation. BM cells from B6 primary chimeric recipients were isolated on the basis of CD45 isoforms. ) of CD45.1/2 (F1) competitors. Each transplant group consisted of five recipients and blood samples (60 ml) were taken on a monthly basis to determine donor chimerism and CRI.
Statistical analysis P-values were calculated using the Mann-Whitney test or the Student's t-test (assuming unequal variances of the two variables) and were employed to determine the statistical significance between mobilized blood and normal BM (Po0.05). Quantification of CAFC at days 7 and 35 was performed by using maximum likelihood ratio method. 20 The Poisson-based limiting dilution analysis calculation was used with a 95% confidence interval (CI) to determine significant differences at Po0.05. To verify the in vitro results, three groups of lethally irradiated mice were transplanted in a competitive repopulation assay. Donor chimerism levels of MPB cells were used to calculate CRI post transplant ( Figure 1b ) and were B20% (data not shown). As expected, a CRI value of 1 was maintained throughout the 7-month transplant period for recipient mice receiving CD45.1 BM mixed with GFP BM, indicating equal competitive repopulating ability of both sources (Figure 1b) . However, mice transplanted with MPB in competition with either CD45.1 BM or GFP BM exhibited significantly lower average CRI levels (0.3370.41 and 0.4170.29, respectively) at 5 months after transplant (Figure 1b) .
Results
Unfractionated
Both in vitro CAFC results and in vivo competitive repopulation assays suggest that unfractionated MPB cells have lower repopulation ability compared to unfractionated BM cells. In addition, no apparent differences were observed between different donor mouse strains. The fact that we used the mononuclear cell fraction from mobilized blood (which is enriched for stem cells) and unseparated BM cells may underestimate the difference in repopulating ability.
MPB cells have a lower frequency of LSK cells
We next determined whether the poor repopulation ability of unfractionated MPB cells is reflected by the size of the phenotypically defined stem cell population, LSK. To test this possibility we measured LSK frequencies in BM cells and MPB. Typical FACS plots for isolating LSK cells from BM and MPB cells are shown in Figure 2a and b. MPB differs from BM cells, as they contain fewer c-Kit þ cells and more Sca-1 À c-Kit À cells (Figure 2b ). This finding is consistent with that of Levesque et al., 21 who reported that mobilization with G-CSF results in a downregulation of c-Kit on mouse hematopoietic progenitor cells in vivo. On average, BM cells have a LSK frequency of 0.1770.1%, significantly different to that of MPB cells, which have a three-to four-fold lower frequency of 0.0570.04% (Po0.05) ( Table 1 ). The lower frequency in mobilized blood may explain the lower repopulation potential of unfractionated mobilized blood.
To compare mobilized blood and BM LSK on a per cell basis, LSK cells were isolated from BM and MPB and placed in limiting dilution in a CAFC assay to assess clonogenic activity. CAFC day 7 frequency of 250/10 3 LSK cells (153-402; 95% CI) was recorded for control BM LSK cells, whilst MPB LSK cells had a 2.4-fold higher CAFC (Figure 2a and b) . Thus, these data suggest that, compared to BM, MPB LSK cells contain somewhat more progenitor cells, but slightly fewer stem cells.
It is well known that in normal BM all stem cell activity is contained in the LSK fraction. 22, 23 To verify that in mobilized blood, stem cell activity is also restricted to the LSK population, Lin À cells from MPB were further fractionated into non-Sca-1 þ c-Kit þ cells and placed in limiting dilution in a CAFC assay (Figure 2c ). As shown in Figure 2c , only some day 7 CAFC activity was detected for Lin À non-Sca-1 þ c-Kit þ cells, but no CAFC day 35. This demonstrates that cells outside the LSK gate do not have clonogenic activity. A summary of LSK frequencies and CAFC day 35 frequencies and a calculation of their total pool size is shown in Table 1 . As we did not splenectomize our mice, a considerable number of LSK cells may have been present in the spleen. However, we aimed at comparing the phenotypically defined cell population (LSK) from mobilized blood with the same population in steady-state BM. Table 1 for details). suggests that the frequency of cells that contribute to long-term repopulation is at limiting dilution; 1250 MPB LSK cells contain very few (0, 1 or 2) stem cells. This is consistent with our CRU data (0.75 CRU/100 LSK). Reducing the dose of BM LSK to 625 led to more variation in chimerism but overall levels were still higher (52734%) than those observed in some recipients transplanted with 1250 MPB LSK.
Discussion
In the present study, we exploited a murine model to evaluate the quality of MPB stem cells in in vitro and in vivo assays. Our data demonstrated that unfractionated MPB stem cells have a five-fold reduction in CAFC day 35 activity and a five-fold reduction in stem cell repopulation potential compared to unfractionated control BM cells (Figure 1) . Mobilized blood stem cells, selected on basis of LSK expression, displayed an even greater fold reduction (25-fold) in long-term repopulation potential when transplanted in competition with normal BM stem cells (Figure 4) . Limiting dilution analysis showed that this was a result of fewer stem cells rather than less potent stem cells as mobilized blood stem cells have a 8.8-fold decrease in CRU compared to BM stem cells ( Figure 5 ).
To compensate for the possible differences in stem cell frequency our experiments were performed using a phenotypically defined stem cell population, LSK. Although LSK cells are not a pure stem cell population, in steady-state BM they contain all cells with long-term repopulating ability, very much like CD34 þ cells in humans. 22, 23 The overall LSK cell number in MPB was markedly lower than in the BM pool ( Table 1) . As interstrain variations in stem cell mobilization are reported, 24 it is not unlikely that in other mouse strains G-CSF induced mobilization would lead to higher numbers of LSK cells in the circulation. In mobilized blood, fewer c-Kit þ cells were observed. These data are consistent with a downregulation of c-Kit on mouse hematopoietic progenitor cells in vivo resulting from proteolytic cleavage as previously reported. 21 G-CSF administration also causes a change in cell surface marker expression of CD34. 25 Importantly, we found no in vitro stem cell activity in cells negative for either c-Kit or Sca-1, documenting that also in mobilized blood all stem cells are contained in the LSK population.
Purified In our study, transplantation of purified stem cells from peripheral blood displayed a rapid increase in recovery of WBC counts demonstrating an increase in short-term engraftment, consistent with clinical and experimental data. 2, 3, 31, 32 The observed consistency between clinical and experimental data validates the use of LSK cells in the murine system as a model to study the quality of MPB stem cells. Murine LSK, much like human CD34 þ cells, are predominantly progenitor cells but contain the vast majority of long-term repopulating stem cells.
The observed reduction in the frequency of stem cells rather than a faster deterioration of blood stem cells suggest that recipients should receive higher cell dose of mobilized blood stem cells to compensate for the decrease in repopulation potential. In clinical studies, patients receiving MPB typically receive a much higher CD34 þ cell dose than the BM group. 31, 33 Currently, 15-20 Â 10 4 CFU-GM/kg or 2-2.5 Â 10 6 CD34 þ cells/kg is generally the agreed minimum threshold below which rapid hematopoietic reconstitution may not occur. 4, 34 However, our data cautions the use of the frequency of a phenotypically defined population such as CD34 þ in humans or LSK in mice, as the only parameter for decisions about a minimum cell dose. Although the number of harvested mobilized CD34 þ cells in humans is usually sufficient, our results warrant careful analysis of the long-term repopulation potential of these cells. The presence of fewer long-term repopulating cells within this population will increase the risk of regrowth of host (malignant) hematopoiesis as shown in our non competitive transplants (Figure 7) .
Interestingly, a Bseven-fold difference in CRI was observed between transplants with unfractionated MPB cells (CRI of 0.3170.1) (Figure 1 ) and transplants with mobilized purified blood stem cells (CRI of 0.0470.04) (Figure 4 ). This could be caused by the difference in cells used (mononuclear cells for MPB and unseparated (480% granuloid) cells from BM, or it may suggest a potential role of accessory cells to facilitate engraftment of MPB cells. It was reported that a CD8
þ /TCR À cell population from the donor BM facilitates engraftment of purified allogeneic BM stem cells. 35 MPB LSK cells may be more dependent on accessory cells than BM stem cells. Thus, it is possible that during the purification of LSK cells from MPB, accessory cells facilitating engraftment were lost, leading to a further decrease in repopulation of purified MPB stem cells.
In summary, although MPB stem cells promote faster hematological recovery, our competitive and non-competitive transplant models suggest that their lower stem cell frequency affects the long-term repopulation potential of blood LSK stem cells in mice.
